The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery

IF 2.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2025-05-27 DOI:10.1111/cen.15262

Xi Wang, Hailu Ma, Fang Wang, Hongmei Long, Chenyang Li, Min Nie, Qin Han, Jiangfeng Mao, Xueyan Wu

{"title":"The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery","authors":"Xi Wang, Hailu Ma, Fang Wang, Hongmei Long, Chenyang Li, Min Nie, Qin Han, Jiangfeng Mao, Xueyan Wu","doi":"10.1111/cen.15262","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Hypothalamic obesity, weight gain dominantly due to hypothalamic dysfunction, is a challenge for patients with craniopharyngioma surgery. Semaglutide, a long-acting GLP-1 receptor agonist, has shown promise in obesity management. However, the efficacy in this specific patient population remains underexplored.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aimed to evaluate the efficacy of semaglutide on weight reduction in patients with craniopharyngioma surgery.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A prospective clinical study was conducted involving 23 patients with obesity after craniopharyngioma surgery who attended the outpatient endocrinology department at Peking Union Medical College Hospital from March 2023 to October 2024. Patients were divided into a treatment group receiving semaglutide (<i>n</i> = 14) and a control group undergoing lifestyle intervention alone (<i>n</i> = 9). Parameters including weight, BMI, waist circumference, blood glucose and lipid profiles, were collected at baseline, 3 and 6 months of treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The treatment group showed a significant reduction in weight after 3 months (108.9 ± 20.9 kg vs. 100.8 ± 20.2 kg, <i>p</i> < 0.001) and after 6 months (108.9 ± 20.9 kg vs. 96.1 ± 23.1 kg, <i>p</i> < 0.001). Conversely, the control group experienced weight gain over the same periods. After 3 months, 64.3% of patients in the treatment group achieved weight loss greater than 5%. And after 6 months this rate increased to 90%.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Semaglutide demonstrated significant effects on weight loss in patients with hypothalamic obesity with craniopharyngioma surgery, providing a viable option for managing obesity in this population.</p>\n \n <p><b>Trial Registration:</b> ChiCTR2400094933.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"103 3","pages":"359-365"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hypothalamic obesity, weight gain dominantly due to hypothalamic dysfunction, is a challenge for patients with craniopharyngioma surgery. Semaglutide, a long-acting GLP-1 receptor agonist, has shown promise in obesity management. However, the efficacy in this specific patient population remains underexplored.

Objective

This study aimed to evaluate the efficacy of semaglutide on weight reduction in patients with craniopharyngioma surgery.

Methods

A prospective clinical study was conducted involving 23 patients with obesity after craniopharyngioma surgery who attended the outpatient endocrinology department at Peking Union Medical College Hospital from March 2023 to October 2024. Patients were divided into a treatment group receiving semaglutide (n = 14) and a control group undergoing lifestyle intervention alone (n = 9). Parameters including weight, BMI, waist circumference, blood glucose and lipid profiles, were collected at baseline, 3 and 6 months of treatment.

Results

The treatment group showed a significant reduction in weight after 3 months (108.9 ± 20.9 kg vs. 100.8 ± 20.2 kg, p < 0.001) and after 6 months (108.9 ± 20.9 kg vs. 96.1 ± 23.1 kg, p < 0.001). Conversely, the control group experienced weight gain over the same periods. After 3 months, 64.3% of patients in the treatment group achieved weight loss greater than 5%. And after 6 months this rate increased to 90%.

Conclusion

Semaglutide demonstrated significant effects on weight loss in patients with hypothalamic obesity with craniopharyngioma surgery, providing a viable option for managing obesity in this population.

Trial Registration: ChiCTR2400094933.

查看原文本刊更多论文

西马鲁肽治疗颅咽管瘤术后下丘脑肥胖的疗效观察。

背景：下丘脑肥胖，体重增加主要是由于下丘脑功能障碍，是颅咽管瘤手术患者面临的挑战。Semaglutide是一种长效GLP-1受体激动剂，在肥胖治疗中显示出前景。然而，对这一特定患者群体的疗效仍有待进一步研究。目的：本研究旨在评价西马鲁肽对颅咽管瘤手术患者减肥的效果。方法：对2023年3月至2024年10月在北京协和医院内分泌科门诊就诊的23例颅咽管瘤术后肥胖患者进行前瞻性临床研究。将患者分为接受西马鲁肽治疗组（n = 14）和单独接受生活方式干预的对照组（n = 9）。在基线、治疗3个月和6个月时收集体重、BMI、腰围、血糖和血脂等参数。结果：治疗组在3个月后体重显著减轻（108.9±20.9 kg vs 100.8±20.2 kg）。结论：Semaglutide对下丘脑肥胖颅咽管瘤手术患者的体重减轻有显著效果，为治疗该人群的肥胖提供了一种可行的选择。试验注册：ChiCTR2400094933。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.